Arcus Biosciences, Inc. (NYSE:RCUS) CEO Buys $201,564.00 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CEO Terry J. Rosen purchased 19,800 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was acquired at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the purchase, the chief executive officer now owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. The trade was a 0.78 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Arcus Biosciences Stock Down 2.7 %

Shares of NYSE:RCUS opened at $9.87 on Friday. The firm has a market cap of $1.04 billion, a P/E ratio of -3.13 and a beta of 0.84. Arcus Biosciences, Inc. has a 12-month low of $9.85 and a 12-month high of $20.10. The business has a fifty day simple moving average of $13.46 and a 200 day simple moving average of $15.42. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.14. The company had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. Analysts predict that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in RCUS. R Squared Ltd bought a new stake in shares of Arcus Biosciences in the 4th quarter valued at $26,000. Point72 Hong Kong Ltd acquired a new position in Arcus Biosciences in the third quarter valued at $47,000. Lazard Asset Management LLC boosted its position in Arcus Biosciences by 3,321.3% during the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock valued at $93,000 after acquiring an additional 6,078 shares during the last quarter. US Bancorp DE grew its holdings in Arcus Biosciences by 2,432.0% during the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock worth $103,000 after acquiring an additional 6,615 shares during the period. Finally, Quest Partners LLC raised its position in shares of Arcus Biosciences by 40,904.3% in the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock worth $144,000 after acquiring an additional 9,408 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on RCUS shares. HC Wainwright raised Arcus Biosciences from a “neutral” rating to a “buy” rating and raised their price objective for the company from $18.00 to $24.00 in a research note on Wednesday. Bank of America reduced their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. Morgan Stanley lowered their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Finally, Wedbush restated an “outperform” rating and issued a $36.00 target price on shares of Arcus Biosciences in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Arcus Biosciences presently has a consensus rating of “Buy” and a consensus target price of $30.25.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.